With roots in China for more than 30 years, Pfizer has become one of the major foreign pharmaceutical companies in China. The new Pfizer will continue to contribute to the realization of "Healthy China 2030".

Pfizer entered the Chinese market in 1989. Currently, Pfizer's operations in China cover more than 300 cities, with a cumulative investment of more than US$1.5 billion, one state-of-the-art manufacturing facility, two R&D centers (located in Zhangjiang Hi-Tech Park in Shanghai and Wuhan Optics Valley), and close to 7,000 employees in China in the areas of business, R&D, and manufacturing. Pfizer markets high-quality, innovative products in five major areas in China, including oncology, vaccines, anti-infectives, inflammation and immunity, rare diseases and other prescription drugs and vaccines, with a strong and comprehensive product line designed to meet the health needs of all stages of life.

With roots in China for more than 30 years, Pfizer continues to introduce more core technologies and resources into China, relying on its global medical resources to actively promote the development of China's healthcare industry.